Skip to main content

Table 2 Procedural data and results

From: N-terminal pro-B-type natriuretic peptide is associated with clinical outcomes after transcatheter aortic valve replacement

 

Total

(n = 357)

Responders

(n = 234)

Non-responders

(n = 123)

P value

Emergency surgery

17(4.8)

13(5.6)

4(3.3)

0.331

Local anesthesia

59(16.6)

40(17.1)

19(15.6)

0.714

Access

   

0.035

Transfemoral

343(96.1)

229(97.9)

114(92.7)

 

Non-transfemoral (Carotid, Subclavian)

14(3.9)

5(2.1)

9(7.3)

 

Valve type

   

0.223

Self-expandable valve (Venus-A, VitaFlow, TaurusOne)

328(91.9)

212(90.6)

116(94.3)

 

Balloon-expandable valve (Sapien3, Sapien XT)

29(8.1)

22(9.4)

7(5.7)

 

Post-procedure AR grade ≥ moderate

5(1.4)

2(0.9)

3(2.4)

0.345

Conversion to open surgery

6(1.7)

2(0.9)

4(3.3)

0.186

 s valve implantation

70(19.6)

41(17.5)

29(23.6)

0.171

Device migration to ventricle

52(14.6)

29(12.4)

23(18.7)

 

Paravalvular leakage

13(3.6)

8(3.4)

5(4.1)

 

Device expand inadequately

5(1.4)

4(1.7)

1(0.8)

 
  1. Values are mean ± SD, n (%), or median (interquartile range)